$CNSP

$5.08 +$0.46 (9.84%) Close

$CNSP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 1.5M shares outstanding

Who owns CNSP?

By type of holder

Institutions 19.2% Insiders 0.9% Everyone else 79.9%

Concentration Top 10 holders own 20.1%

Ikarian Capital, LLC 9.3% · ADAR1 Capital Management, LLC 4.8%

Institutional ownership

19.2%

+9.2 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

+134.8K

by institutions in Q2 2026

New / sold out

4 / 4

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Ikarian Capital, LLC +90.0K
ADAR1 Capital Management, LLC NEW +70.0K

Biggest sellers in Q2 2026

Geode Capital Management, LLC SOLD OUT −23.2K
Stonepine Capital Management, LLC −19.4K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for CNS Pharmaceuticals Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+1293.2%

+1293.23% a year

Each share's claim on the business

−92.8%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $1.03M

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

75.9%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting CNSP on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
IC Ikarian Capital, LLC	135.8K	9.29%	+90.0K (+196.4%)	Q4 '25	0.1%
Shares held by quarter Peak holding135.8K (Q2'26) Change over 8 quarters+135.8K Share of the company9.290% Ikarian Capital, LLC's full portfolio →
AC ADAR1 Capital Management, LLC	70.0K	4.79%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding70.0K (Q2'26) Change over 8 quarters+70.0K Share of the company4.790% ADAR1 Capital Management, LLC's full portfolio →

Ikarian Capital, LLC

135.8K

% of company

9.29%

Change vs last qtr

+90.0K (+196.4%)

Held since

Q4 '25

ADAR1 Capital Management, LLC

70.0K

% of company

4.79%

Change vs last qtr

NEW

Held since

Q2 '26

13 more super investors behind a free account

See every manager holding CNS Pharmaceuticals Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting CNSP on Form N-PORT; together they hold 1.1% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$49.6K	8.3K	0.57%	0.00%	August 31, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$33.4K	7.0K	0.48%	0.00%	June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$49.6K

% of company

0.57%

% of the fund

0.00%

As of

August 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$33.4K

% of company

0.48%

% of the fund

0.00%

As of

June 30, 2026

2 more funds behind a free account

See every fund holding CNS Pharmaceuticals Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
CF Charles Faith L. Insider	7.1K	0.49%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.490% Charles Faith L.'s insider activity →
LR Levin Rami Insider	4.8K	0.33%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company0.330% Levin Rami's insider activity →

Charles Faith L.

Insider

7.1K

% of company

0.49%

Change vs last qtr

—

Held since

—

Levin Rami

Insider

4.8K

% of company

0.33%

Change vs last qtr

—

Held since

—

1 more holders behind a free account

See every insider and 5%+ holder of CNS Pharmaceuticals Inc.

Comments